| Budget Amount *help |
¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1996: ¥300,000 (Direct Cost: ¥300,000)
Fiscal Year 1995: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Research Abstract |
We have reported the data of free radical, catalase and superoxide dismutase (SOD) in human brain tumors, and we measured them again in much more volume of brain tumor tissues. However, the data did not indicate the difference between malignant and benign tumors or the prognosis of the patients with brain tumor.
Recently, we published the cell culture of glioblastoma which obtain from a young female. Now weare studying to see the expression of SOD in the cell culture medium following the administration of anti cancer agents and/or irradiation to the culture cell in invitro.
The expression of SOD in human malignant brain tumors such as anaplastic astrocytomas, glioblastomas medulloblastomas and metastatic tumors, and in human benign brain tumors such as meningiomas, pituitary adenomas and schwannomas which done using an immunohistochemical technique. In general, the expression of SOD was lower in malignant brain tumors than benign tumors. However, higher expression of SOD in malignant brain tumors observed only in recurrent cases. Therefore poor outcome of the patients with malignant brain tumor, may not depend on the positivity of SOD immunostain, due to it's biological behavior.
A focused in malignant brain tumors, better outcome was observed in lower positivity of SOD immunostain and worse outcome in higher positivity. Thus, the measurement of SOD in malignant brain tumors was a good indicator to asses the prognosis of the patients. On the other hand, the outcome of the patients with benign brain tumors was much correlate to the degree of tumor removal than the positivity of SOD in the tumor tissues.
The resistancy of malignant brain tumors to the adjuvant therapies is due to the inadequate or imcomplete chemotherapy and/or radiotherapy. Our next study will be focused to this point and will able to make an effective therapeutic strategy to prevent resistency in the adjuvant therapies.
|
